253 related articles for article (PubMed ID: 29272540)
1. Measures of BSEP Inhibition In Vitro Are Not Useful Predictors of DILI.
Chan R; Benet LZ
Toxicol Sci; 2018 Apr; 162(2):499-508. PubMed ID: 29272540
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Drug-Induced Liver Injury Prediction: Criteria Optimization of Efflux Transporter IC50 and Physicochemical Properties.
Yucha RW; He K; Shi Q; Cai L; Nakashita Y; Xia CQ; Liao M
Toxicol Sci; 2017 Jun; 157(2):487-499. PubMed ID: 28369588
[TBL] [Abstract][Full Text] [Related]
3. A Two-Tiered In Vitro Approach to De-Risk Drug Candidates for Potential Bile Salt Export Pump Inhibition Liabilities in Drug Discovery.
Hafey MJ; Houle R; Tanis KQ; Knemeyer I; Shang J; Chen Q; Baudy A; Monroe J; Sistare FD; Evers R
Drug Metab Dispos; 2020 Nov; 48(11):1147-1160. PubMed ID: 32943412
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of DILI Predictive Hypotheses in Early Drug Development.
Chan R; Benet LZ
Chem Res Toxicol; 2017 Apr; 30(4):1017-1029. PubMed ID: 28257576
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4.
Köck K; Ferslew BC; Netterberg I; Yang K; Urban TJ; Swaan PW; Stewart PW; Brouwer KL
Drug Metab Dispos; 2014 Apr; 42(4):665-74. PubMed ID: 24154606
[TBL] [Abstract][Full Text] [Related]
6. Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Aleo MD; Luo Y; Swiss R; Bonin PD; Potter DM; Will Y
Hepatology; 2014 Sep; 60(3):1015-22. PubMed ID: 24799086
[TBL] [Abstract][Full Text] [Related]
7. Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective.
Kenna JG; Taskar KS; Battista C; Bourdet DL; Brouwer KLR; Brouwer KR; Dai D; Funk C; Hafey MJ; Lai Y; Maher J; Pak YA; Pedersen JM; Polli JW; Rodrigues AD; Watkins PB; Yang K; Yucha RW;
Clin Pharmacol Ther; 2018 Nov; 104(5):916-932. PubMed ID: 30137645
[TBL] [Abstract][Full Text] [Related]
8. Experimental Evidence of Liver Injury by BSEP-Inhibiting Drugs With a Bile Salt Supplementation in Rats.
Yang F; Takeuchi T; Tsuneyama K; Yokoi T; Oda S
Toxicol Sci; 2019 Jul; 170(1):95-108. PubMed ID: 30985903
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Bile Salt Export Pump (BSEP) Inhibition in Membrane Vesicles Using Radioactive and LC/MS-Based Detection Methods.
Marroquin LD; Bonin PD; Keefer J; Schroeter T
Curr Protoc Toxicol; 2017 Feb; 71():14.14.1-14.14.20. PubMed ID: 28146280
[TBL] [Abstract][Full Text] [Related]
10. Use of a Bile Salt Export Pump Knockdown Rat Susceptibility Model to Interrogate Mechanism of Drug-Induced Liver Toxicity.
Li Y; Evers R; Hafey MJ; Cheon K; Duong H; Lynch D; LaFranco-Scheuch L; Pacchione S; Tamburino AM; Tanis KQ; Geddes K; Holder D; Zhang NR; Kang W; Gonzalez RJ; Galijatovic-Idrizbegovic A; Pearson KM; Lebron JA; Glaab WE; Sistare FD
Toxicol Sci; 2019 Jul; 170(1):180-198. PubMed ID: 30903168
[TBL] [Abstract][Full Text] [Related]
11. Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11).
Pedersen JM; Matsson P; Bergström CA; Hoogstraate J; Norén A; LeCluyse EL; Artursson P
Toxicol Sci; 2013 Dec; 136(2):328-43. PubMed ID: 24014644
[TBL] [Abstract][Full Text] [Related]
12. Effect of a Common Genetic Variant (p.V444A) in the Bile Salt Export Pump on the Inhibition of Bile Acid Transport by Cholestatic Medications.
Ali I; Khalid S; Stieger B; Brouwer KLR
Mol Pharm; 2019 Mar; 16(3):1406-1411. PubMed ID: 30608704
[TBL] [Abstract][Full Text] [Related]
13. Moving beyond Binary Predictions of Human Drug-Induced Liver Injury (DILI) toward Contrasting Relative Risk Potential.
Aleo MD; Shah F; Allen S; Barton HA; Costales C; Lazzaro S; Leung L; Nilson A; Obach RS; Rodrigues AD; Will Y
Chem Res Toxicol; 2020 Jan; 33(1):223-238. PubMed ID: 31532188
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Relevance of DILI Predictive Hypotheses in Early Drug Development: Review of
Chan R; Benet LZ
Toxicol Res (Camb); 2018 May; 7(3):358-370. PubMed ID: 29785262
[TBL] [Abstract][Full Text] [Related]
15. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Warner DJ; Chen H; Cantin LD; Kenna JG; Stahl S; Walker CL; Noeske T
Drug Metab Dispos; 2012 Dec; 40(12):2332-41. PubMed ID: 22961681
[TBL] [Abstract][Full Text] [Related]
16. Current Concepts in Drug-Induced Bile Salt Export Pump (BSEP) Interference.
Kenna JG
Curr Protoc Toxicol; 2014 Aug; 61():23.7.1-15. PubMed ID: 25104267
[TBL] [Abstract][Full Text] [Related]
17. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Morgan RE; Trauner M; van Staden CJ; Lee PH; Ramachandran B; Eschenberg M; Afshari CA; Qualls CW; Lightfoot-Dunn R; Hamadeh HK
Toxicol Sci; 2010 Dec; 118(2):485-500. PubMed ID: 20829430
[TBL] [Abstract][Full Text] [Related]
18. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Dawson S; Stahl S; Paul N; Barber J; Kenna JG
Drug Metab Dispos; 2012 Jan; 40(1):130-8. PubMed ID: 21965623
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of bile salt transport by drugs associated with liver injury in primary hepatocytes from human, monkey, dog, rat, and mouse.
Zhang J; He K; Cai L; Chen YC; Yang Y; Shi Q; Woolf TF; Ge W; Guo L; Borlak J; Tong W
Chem Biol Interact; 2016 Aug; 255():45-54. PubMed ID: 27000539
[TBL] [Abstract][Full Text] [Related]
20. A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Morgan RE; van Staden CJ; Chen Y; Kalyanaraman N; Kalanzi J; Dunn RT; Afshari CA; Hamadeh HK
Toxicol Sci; 2013 Nov; 136(1):216-41. PubMed ID: 23956101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
